Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: Physician knowledge, patient adherence

被引:7
|
作者
Solem, Caitlyn [1 ]
Mody, Reema [2 ]
Stephens, Jennifer [1 ]
Macahilig, Cynthia [3 ]
Gao, Xin [1 ]
机构
[1] Pharmerit North Amer, Bethesda, MD 20814 USA
[2] Takeda Pharmaceut Int, Deerfield, IL USA
[3] Market Certitude Med Data Analyt, Parsippany, NJ USA
关键词
Gastroesophageal reflux disease; proton-pump inhibitors; survey; adherence; physicians; patients;
D O I
10.1331/JAPhA.2014.13117
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To describe physicians' knowledge, patients' adherence, and perceptions of both regarding mealtime-related dosing directions for proton-pump inhibitors (PPIs). Design: Chart review and survey of patients and physicians. Setting: United States, with data collected between January and July 2011. Participants: Patients being treated for gastroesophageal reflux disease (GERD) with PPIs and their prescribing physicians. Main outcome measures: Patient-and physician-reported perception of PPI mealtime-related directions as important/ inconvenient (seven-point Likert scale; 7 = very important/ very inconvenient); physician-reported knowledge of PPI mealtime-related dosing directions based on whether the agent is labeled to be taken 30-60 minutes before eating (DIR-esomeprazole magnesium [Nexium-AstraZeneca], lansoprazole, and omeprazole) or labeled to be taken regardless of meals (NoDIR-dexlansoprazole [Dexilant-Takeda], rabeprazole, and pantoprazole); and patient-reported PPI mealtime-related directions received and adherence to directions. Results: Physicians (n = 262) recruited 501 patients who had been prescribed PPIs (262 DIR/239 NoDIR; mean age 51 years, 37% men, 56% nonerosive GERD [29% undocumented]). Across PPIs, physicians frequently reported incorrect directions or "did not know directions" (29% for esomeprazole to 69% for pantoprazole). While 98% of patients reported receiving directions from their physicians and 55% from their pharmacists, only 65% of DIR patients and 18% of NoDIR received directions consistent with product labeling. Physicians perceived greater inconvenience than patients (4.4 vs. 1.6, P < 0.001) and greater importance (5.2 vs. 4.5, P < 0.001) of mealtime-related directions. Overall, 81% of patients reported taking their PPI as directed. Conclusion: While this patient cohort was adherent to directions given, physicians' directions were often inconsistent with product labeling. Understanding physician and patient knowledge gaps may be critical to ensuring patients receive appropriate directions, improving patient adherence to specific dosing instructions, attaining positive therapy outcomes, and identifying opportunities for pharmacist-led interventions.
引用
收藏
页码:144 / 153
页数:10
相关论文
共 50 条
  • [41] Increased Proximal Reflux in a Hypersensitive Esophagus Might Explain Symptoms Resistant to Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease
    Rohof, Wout O.
    Bennink, Roelof J.
    de Jonge, Hugo
    Boeckxstaens, Guy E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (10) : 1647 - 1655
  • [42] Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
    Mermelstein, Joseph
    Mermelstein, Alanna Chait
    Chait, Maxwell M.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2016, 9 : 163 - 172
  • [43] Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: A systematic review
    Liu, Qing
    Feng, Chen-Chen
    Wang, Er-Man
    Yan, Xiu-Juan
    Chen, Sheng-Liang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (47) : 9111 - 9118
  • [44] Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients
    Grigolon, Ausilia
    Cantu, Paolo
    Savojardo, Daniela
    Conte, Dario
    Penagini, Roberto
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (09) : 969 - 973
  • [45] Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: A systematic review
    Qing Liu
    Chen-Chen Feng
    Er-Man Wang
    Xiu-Juan Yan
    Sheng-Liang Chen
    World Journal of Gastroenterology, 2013, (47) : 9111 - 9118
  • [46] What is proton pump inhibitors unresponsiveness in gastroesophageal reflux disease? How should these cases be managed?
    Celebi, Altay
    Yilmaz, Hasan
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2017, 28 : S71 - S72
  • [47] Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea
    Park, Susan
    Park, Sungsoo
    Park, Joong-Min
    Ryu, Soorack
    Hwang, Jinseub
    Kwon, Jin-Won
    Seo, Kyung Won
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 26 (02) : 215 - 223
  • [48] Assessment of columnar-lined esophagus in controls and patients with gastroesophageal reflux disease with and without proton-pump inhibitor therapy
    I. Mesteri
    J. Lenglinger
    L. Beller
    S. Fischer-See
    Sebastian F. Schoppmann
    F. Wrba
    F. M. Riegler
    J. Zacherl
    European Surgery, 2012, 44 : 304 - 313
  • [49] Assessment of columnar-lined esophagus in controls and patients with gastroesophageal reflux disease with and without proton-pump inhibitor therapy
    Mesteri, I.
    Lenglinger, J.
    Beller, L.
    Fischer-See, S.
    Schoppmann, Sebastian F.
    Wrba, F.
    Riegler, F. M.
    Zacherl, J.
    EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2012, 44 (05): : 304 - 313
  • [50] Maintenance Treatment of Mild Gastroesophageal Reflux Disease with Proton Pump Inhibitors Taken On-Demand: A Meta-Analysis
    Jiang, Yuan-Xi
    Chen, Ying
    Kong, Xuan
    Tong, Yi-Li
    Xu, Shu-Chang
    HEPATO-GASTROENTEROLOGY, 2013, 60 (125) : 1077 - 1082